Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10544 participants.
Also called NCT03071692
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 10,544 participants
- Registry
-
NCT03071692
-
- Other papers using this trial's data
- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, France, Germany, Hungary, India, Israel, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03071692. Randomized; quadruple masking; primary purpose prevention. Start 2017-03-23 (actual); primary completion 2022-07-27 (actual). Results posted on 2025-09-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
- Acronym
- PROMINENT
- Condition
- Type2 Diabetes
- Condition
- Dyslipidemia
- Intervention (Drug)
- K-877
- Intervention (Drug)
- Placebo
- Lead sponsor
- Kowa Research Institute, Inc.
- Collaborator
- Brigham and Women's Hospital
Record details
- Record id
cardio:ct-nct03071692- Content hash
237abfeab941a1a7e993c75b8d99d30b20c1abf4b2adc985c5de144812f51edc